Nandyala Arathi S, Suri Himanshu, Dougherty Carrie O, Ailani Jessica
MedStar Georgetown University Hospital, Washington DC, USA.
MedStar Georgetown University Hospital, Washington DC, USA.
Clin Neurol Neurosurg. 2022 Apr;215:107200. doi: 10.1016/j.clineuro.2022.107200. Epub 2022 Mar 7.
Prior to the approval of erenumab, onabotulinum toxin A (onabot A) was the only Food and Drug Administration-approved chronic migraine preventive treatment. In this study, we assess the safety and efficacy of the combination of erenumab and onabot A for chronic migraine prevention.
This is a retrospective cohort study of patients with a diagnosis of chronic migraine receiving onabot A, who were additionally started on erenumab. Primary endpoint was a decrease in number of migraine days while on the combination treatment as compared to onabot A alone. Secondary endpoints included a decrease in headache days and reported side effects.
When erenumab was added to onabot A, participants (n = 50) experienced significantly lower number of monthly migraine days (11.3 ± 9.3 vs. 14.9 ± 9.4, p < 0.001). The treatment of onabot A and erenumab also significantly lowered the number of monthly headache days (18.2 ± 10.3 vs. 20.7 ± 9.1, p = 0.042). There were no "severe" adverse effects reported in the combined treatment group.
This retrospective case series showed a reduction in monthly migraine and headache days with the treatment combination of erenumab and onabot A compared to onabot A alone in patients with chronic migraine.
在erenumab获批之前，A型肉毒毒素（onabot A）是美国食品药品监督管理局批准的唯一一种慢性偏头痛预防性治疗药物。在本研究中，我们评估erenumab与onabot A联合用于预防慢性偏头痛的安全性和有效性。
这是一项对诊断为慢性偏头痛且正在接受onabot A治疗、并额外开始使用erenumab的患者进行的回顾性队列研究。主要终点是联合治疗期间与单独使用onabot A相比偏头痛天数的减少。次要终点包括头痛天数的减少和报告的副作用。
当erenumab添加到onabot A中时，参与者（n = 50）每月偏头痛天数显著减少（11.3±9.3对14.9±9.4，p < 0.001）。onabot A和erenumab联合治疗也显著降低了每月头痛天数（18.2±10.3对20.7±9.1，p = 0.042）。联合治疗组未报告“严重”不良反应。
该回顾性病例系列研究表明，与单独使用onabot A相比，erenumab与onabot A联合治疗可减少慢性偏头痛患者的每月偏头痛天数和头痛天数。
